Phase II trial of subcutaneous interferon followed by intravenous hybrid bolus/continuous infusion interleukin-2 in the treatment of renal cell carcinoma: final results of Cancer Biotherapy Research Group 95-09.

Dillman, Robert O; Wiemann, Michael C; Tai, D Fritz; Depriest, Carol B; Soori, Gamini; Stark, James J; Mahdavi, Khosrow; Church, Curtis K

Dillman, Robert O; Wiemann, Michael C; Tai, D Fritz; Depriest, Carol B; Soori, Gamini; Stark, James J; Mahdavi, Khosrow; Church, Curtis K.

Affiliation

Dillman RO; Hoag Cancer Center, Newport Beach, CA 92658, USA. rdillman@hoaghospital.org

Cancer Biother Radiopharm ; 21(2): 130-7, 2006 Apr.

Article in En | MEDLINE | ID: mdl-16706633

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Carcinoma, Renal Cell/drug therapy; Kidney Neoplasms/drug therapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Carcinoma, Renal Cell/pathology; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha/administration & dosage; Interferon-alpha/adverse effects; Interleukin-2/administration & dosage; Interleukin-2/adverse effects; Kidney Neoplasms/pathology; Male; Middle Aged; Neoplasm Metastasis; Recombinant Proteins

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Antineoplastic Combined Chemotherapy Protocols / Kidney Neoplasms Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Cancer Biother Radiopharm Journal subject: FARMACIA / FARMACOLOGIA / NEOPLASIAS / TERAPEUTICA Year: 2006 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links